Innohep (Tinzaparin Sodium)

Innohep is a low molecular weight heparin used in the management of venous thrombo‑embolism and related conditions.

• Prevention of deep vein thrombosis (DVT) in surgical patients: reduces the risk of clot formation after orthopedic or abdominal surgery.
• Treatment of acute deep vein thrombosis: helps dissolve existing clots and prevents extension.
• Prevention of pulmonary embolism: lowers the chance of clot migration to the lungs.
• Prevention of clot formation in acute coronary syndromes: limits thrombus growth during unstable angina or myocardial infarction.

• Tinzaparin sodium potentiates antithrombin III, which accelerates the inhibition of activated factor Xa and, to a lesser extent, factor IIa (thrombin). By reducing the generation of thrombin and subsequent fibrin formation, it interferes with the coagulation cascade, thereby preventing clot propagation and new clot formation in the venous system.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Injection site pain or erythema: localized discomfort at the subcutaneous site.
• Bruising or hematoma: minor bleeding under the skin.
• Mild bleeding: such as epistaxis or gum bleeding.
• Thrombocytopenia: modest reduction in platelet count.
• Elevated liver enzymes: transient increase in hepatic transaminases.
• Nausea or abdominal discomfort.

Serious or Rare Side Effects

• Major bleeding: life‑threatening hemorrhage in gastrointestinal or intracranial sites.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet activation.
• Spinal or epidural hematoma: risk after neuraxial procedures.
• Severe allergic reaction: anaphylaxis or angioedema.
• Paradoxical thrombosis: new clot formation despite therapy.
• Acute liver failure: rare but serious hepatic injury.

Prior to initiating Innohep, clinicians should assess patient‑specific risk factors and monitor laboratory parameters.

• Renal impairment: adjust dose or avoid in severe dysfunction.
• Hepatic impairment: use with caution and monitor liver function.
• Concomitant anticoagulants or antiplatelet agents: increase bleeding risk.
• Recent surgery or trauma: evaluate bleeding risk before administration.
• Pregnancy and breastfeeding: only if potential benefit outweighs risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Innohep may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, direct thrombin inhibitors): additive anticoagulant effect.
• Antiplatelet agents (e.g., aspirin, clopidogrel): heightened bleeding risk.
• Fibrinolytic therapy (e.g., alteplase): synergistic hemorrhagic potential.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase minor bleeding.
• Certain antibiotics (e.g., quinolones): can affect platelet function.
• Hormonal therapies (e.g., estrogen): modestly raise thrombosis risk.